Home Newsfeeds Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Raymond James analyst Steven Seedhouse maintains NexImmune (NASDAQ:NEXI) with a Outperform and lowers the price target from $12 to $3.

byBenzinga Newsdesk

August 16, 2022

1 minute read

Raymond James analyst Steven Seedhouse maintains NexImmune (NASDAQ:NEXI) with a Outperform and lowers the price target from $12 to $3.

BitMex Founder Dumps ‘Sam Coin POS’ For ‘Archangel Vitalik’ Ethereum: Here’s Why

By Murtuza Merchant

December 22, 1:19 PM

Arthur Hayes, the enigmatic co-founder of BitMEX, raised eyebrows when he announced a shakeup of his portfolio.

$BONK

Journey Medical Corporation Expects Topline Results From The Phase 3 Clinical Trials Evaluating DFD-2 For The Treatment Of Papulopustular Rosacea To Be Announced Week Of July 10, 2023

By Happy Mohamed

July 3, 8:02 AM

Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products

DERM

Deutsche Bank Maintains Hold on Illinois Tool Works, Lowers Price Target to $189

By Benzinga Newsdesk

July 13, 11:04 AM

Deutsche Bank analyst Nicole Deblase maintains Illinois Tool Works (NYSE:ITW) with a Hold and lowers the price target from $229 to $189.

ITW

Demand Soars For Novo Nordisk’s Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition

By Benzinga Neuro

May 2, 5:48 AM

The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly.

CTLT

Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Related Posts

BitMex Founder Dumps ‘Sam Coin POS’ For ‘Archangel Vitalik’ Ethereum: Here’s Why

Journey Medical Corporation Expects Topline Results From The Phase 3 Clinical Trials Evaluating DFD-2 For The Treatment Of Papulopustular Rosacea To Be Announced Week Of July 10, 2023

Deutsche Bank Maintains Hold on Illinois Tool Works, Lowers Price Target to $189

Demand Soars For Novo Nordisk’s Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition